Long-term Outcomes of Heart Failure Patients Who Received Primary Prevention Implantable Cardioverter-defibrillator: An Observational Study

Overview

Journal J Arrhythm

Publisher Wiley

Date 2018 May 4

PMID 29721113

Citations 5

Authors

Khang-Li Looi

Karishma Sidhu

Lisa Cooper

Liane Dawson

Debbie Slipper

Andrew Gavin

Nigel Lever

Affiliations

Soon will be listed here.

Abstract

Background: Implantable cardioverter-defibrillator (ICD) therapy is indicated for selected heart failure patients for the primary prevention of sudden cardiac death. Little is known about the outcomes in patients selected for primary prevention device therapy in the northern region of New Zealand.

Method: Heart failure patients with systolic dysfunction who underwent primary prevention ICD/cardiac resynchronization therapy-defibrillator (CRT-D) implantation between January 1, 2007, and June 1, 2015, were included. Complications, mortality, and hospitalization events were reviewed.

Results: Three hundred and eighty-five primary prevention devices were implanted (269 ICD, 116 CRT-D). Mean age at implant was 59.1 ± 11.4 years. Mean duration of follow-up was 3.64 ± 2.17 years. The commonest cause of death was heart failure (41.8%). Only 2 patients died from sudden arrhythmic death. The 5-year heart failure mortality rate was 6%, whereas the 5-year sudden arrhythmic death rate was 0.3%. Heart failure hospitalizations were commoner in those who received ICD than CRT-D (67.7% vs 25.8%, < .001). Maori patients have low implant rates (14%) with relatively high rates of admissions with heart failure and ventricular arrhythmia admissions.

Conclusions: Even in appropriately selected heart failure patients who received primary prevention devices, only a small percentage died as a result of sudden arrhythmic death. CRT-D should be the device of choice where appropriate in heart failure patients. Significant challenges remain to improve access to device therapy and maximize benefit to those who do get implanted.

Citing Articles

Primary Prevention Implantable Cardiac Defibrillators: A Townsville District Perspective.

Engstrom N, Dobson G, Ng K, Letson H Front Cardiovasc Med. 2020; 7:577248.

PMID: 33195463 PMC: 7652736. DOI: 10.3389/fcvm.2020.577248.

The Limitations of Symptom-based Heart Failure Management.

Papadimitriou L, Moore C, Butler J, Long R Card Fail Rev. 2019; 5(2):74-77.

PMID: 31179015 PMC: 6546002. DOI: 10.15420/cfr.2019.3.2.

Outcomes of patients with heart failure after primary prevention ICD unit generator replacement.

Looi K, Gavin A, Cooper L, Dawson L, Slipper D, Lever N Heart Asia. 2019; 11(1):e011162.

PMID: 31031836 PMC: 6454329. DOI: 10.1136/heartasia-2018-011162.

Incidence, Predictors, and Outcomes of Implantable Cardioverter-Defibrillator Discharge Among People Living With HIV.

Alvi R, Neilan A, Tariq N, Awadalla M, Rokicki A, Hassan M J Am Heart Assoc. 2018; 7(18):e009857.

PMID: 30371221 PMC: 6222938. DOI: 10.1161/JAHA.118.009857.

Long-term outcomes of heart failure patients who received primary prevention implantable cardioverter-defibrillator: An observational study.

Looi K, Sidhu K, Cooper L, Dawson L, Slipper D, Gavin A J Arrhythm. 2018; 34(1):46-54.

PMID: 29721113 PMC: 5828273. DOI: 10.1002/joa3.12027.

References

Plummer C, Irving R, McComb J . The incidence of implantable cardioverter defibrillator indications in patients admitted to all coronary care units in a single district. Europace. 2005; 7(3):266-72. DOI: 10.1016/j.eupc.2005.01.006. View

Bogale N, Witte K, Priori S, Cleland J, Auricchio A, Gadler F . The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. Eur J Heart Fail. 2011; 13(9):974-83. DOI: 10.1093/eurjhf/hfr085. View

Mond H, Whitlock R . The Australian and New Zealand cardiac pacing and implantable cardioverter-defibrillator survey: calendar year 2005. Heart Lung Circ. 2007; 17(2):85-9. DOI: 10.1016/j.hlc.2007.06.524. View

Romeyer-Bouchard C, Da Costa A, Dauphinot V, Messier M, Bisch L, Samuel B . Prevalence and risk factors related to infections of cardiac resynchronization therapy devices. Eur Heart J. 2009; 31(2):203-10. DOI: 10.1093/eurheartj/ehp421. View

Wasywich C, Gamble G, Whalley G, Doughty R . Understanding changing patterns of survival and hospitalization for heart failure over two decades in New Zealand: utility of 'days alive and out of hospital' from epidemiological data. Eur J Heart Fail. 2010; 12(5):462-8. DOI: 10.1093/eurjhf/hfq027. View

Linde C, Abraham W, Gold M, St John Sutton M, Ghio S, Daubert C . Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008; 52(23):1834-1843. DOI: 10.1016/j.jacc.2008.08.027. View

Deo R, Albert C . Epidemiology and genetics of sudden cardiac death. Circulation. 2012; 125(4):620-37. PMC: 3399522. DOI: 10.1161/CIRCULATIONAHA.111.023838. View

Scott P, Whittaker A, Zeb M, Watts E, Yue A, Roberts P . Rates of upgrade of ICD recipients to CRT in clinical practice and the potential impact of the more liberal use of CRT at initial implant. Pacing Clin Electrophysiol. 2011; 35(1):73-80. DOI: 10.1111/j.1540-8159.2011.03255.x. View

Mond H, Crozier I . The Australian and New Zealand cardiac pacemaker and implantable cardioverter-defibrillator survey: calendar year 2013. Heart Lung Circ. 2014; 24(3):291-7. DOI: 10.1016/j.hlc.2014.09.017. View

10.

Goldman L . Cost-effectiveness in a flat world--can ICDs help the United States get rhythm?. N Engl J Med. 2005; 353(14):1513-5. DOI: 10.1056/NEJM2e058214. View

11.

Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N . Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation. 2007; 116(12):1349-55. DOI: 10.1161/CIRCULATIONAHA.106.678664. View

12.

Tang A, Wells G, Talajic M, Arnold M, Sheldon R, Connolly S . Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010; 363(25):2385-95. DOI: 10.1056/NEJMoa1009540. View

13.

Tukuitonga C, Bindman A . Ethnic and gender differences in the use of coronary artery revascularisation procedures in New Zealand. N Z Med J. 2002; 115(1152):179-82. View

14.

MOSS A, Hall W, Cannom D, Daubert J, Higgins S, Klein H . Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996; 335(26):1933-40. DOI: 10.1056/NEJM199612263352601. View

15.

Riddell T . Heart failure hospitalisations and deaths in New Zealand: patterns by deprivation and ethnicity. N Z Med J. 2005; 118(1208):U1254. View

16.

Al-Khatib S, Sanders G, Carlson M, Cicic A, Curtis A, Fonarow G . Preventing tomorrow's sudden cardiac death today: dissemination of effective therapies for sudden cardiac death prevention. Am Heart J. 2008; 156(4):613-22. DOI: 10.1016/j.ahj.2008.05.027. View

17.

Carson P, Anand I, OConnor C, Jaski B, Steinberg J, Lwin A . Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005; 46(12):2329-34. DOI: 10.1016/j.jacc.2005.09.016. View

18.

McHale B, Harding S, Lever N, Larsen P . A national survey of clinician's knowledge of and attitudes towards implantable cardioverter defibrillators. Europace. 2009; 11(10):1313-6. DOI: 10.1093/europace/eup236. View

19.

Smith W . New Zealand primary implantable cardioverter defibrillator implantation and biventricular pacing guidelines. N Z Med J. 2010; 123(1309):86-96. View

20.

Bardy G, Lee K, Mark D, Poole J, Packer D, Boineau R . Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352(3):225-37. DOI: 10.1056/NEJMoa043399. View